目的 探讨儿童专科临床药师对新型冠状病毒肺炎患儿的药物治疗及开展药学监护的方法。方法 通过参与我院首例儿童新型冠状病毒肺炎治疗儿童用药方案制定、药物重整、合理用药指导、分析用药过程中可能出现的药物相互作用和不良反应。结果 患儿先后予清热利湿、祛邪扶正类中成药口服,雾化吸入干扰素抗病毒,经过治疗呼吸道标本核酸转为阴性,患儿治愈出院,预后良好。结论 临床药师以药学服务为切入点,参与儿童新型冠状病毒肺炎的防治与药学监护,对保障儿童用药的有效性、合理性及安全性提供帮助,提高用药依从性。
Abstract
OBJECTIVE To investigate the methods of pharmaceutical treatment and care of COVID-19 in child by clinical pharmacist. METHODS Clinical pharmacist was involved in the treatment of the first case of COVID-19 in child in our hospital and provided the full range of clinical pharmacy services, assisting phyicians to optimize the medication regimen, on the basis of the patient's condition and laboratory results,combined with clinical practice. Potential drug interactions and adverse reactions were analyzed during treatment through drug recombination and monitor the efficacy of therapy. RESULTS The child was treated with traditional Chinese medicine by orally, inhaled atomized interferon antivira and was RT-PCR negative for SARS-CoV-2 after treatment. CONCLUSION Clinical pharmacists should use pharmaceutical care as an entry point to participate in the prevention and treatment of COVID-19. The drug monitoring service will conductive to improving the effectiveness, rationality, and safety of children's medication while improving medication compliance.
关键词
新型冠状病毒肺炎 /
儿童 /
临床药师 /
药学监护 /
合理用药
{{custom_keyword}} /
Key words
COVID-19 /
child /
clinical pharmacist /
pharmaceutical care /
rational drug use
{{custom_keyword}} /
中图分类号：
R969.3
R511
R183
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] CHAN J F, YUAN S F, KOK K H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster[J]. Lancet, 2020, 395(10223): 514-523.
[2] CAI J, XU J, LIN D, et al. A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features[J]. Clin Infect Dis, 2020. DOI:10.1093/cid/cioa198.
[3] CHEN F, LIU Z S, ZHANG F R, et al. First case of severe childhood novel coronavirus pneumonia in China[J]. Chin J Pediatr(中华儿科杂志), 2020, 58(3): 179-183.
[4] LI H, TAN X C, JIANG D, et al. Research progress on coronavirus and its therapeutic drugs[J]. Chin Pharm J(中国药学杂志), 2020, 55(4): 284-292.
[5] NATIONAL ATIONAL ADMINISTRATION OF TRADITIONAL CHINESE MEDICINE, NATIONAL HEALTH COMMISSION OF THE PEOPLE, SREPUBLIC OF CHINA. Diagnosis and treatment plan for COVID-19 (Trial version 6)[J]. Chin Med J (Engl). 2020. DOI:10.1097/CM9.0000000000000819
[6] CAI J H, WANG X S, GE Y L, et al. First case of 2019 novel coronavirus infection in children in Shanghai[J]. Chin J Pediatr(中华儿科杂志), 2020, 58(2): 86-87.
[7] HAN Y Y, ZHAO M R, SHI Y, et al. Application of integrative medicine protocols in treatment of coronavirus disease 2019[J]. Chin Tradit Herb Drugs(中草药), 2020, 51(4): 878-882.
[8] LIU J, FAN M Y, SUN K B, et al. Exploring active ingredients and function mechanism of Chaihu Guizhi Ganjiang Decoction against coronavirus disease 2019 based on molecular docking technology[J]. Chin Tradit Herb Drugs(中草药), 2020, 51(7): 1704-1712.
[9] GU M, LIU J, SHI N N, et al. Analysis of property and efficacy of traditional Chinese medicine in staging revention and treatment of coronavirus disease 2019[J]. China J Chin Mater Med(中国中药杂志), 2020, 45(6): 1253-1258.
[10] SHEN K L, SHANG Y X, ZHANG G C, et al. Expert consensus on the rational application of interferon alpha in pediatrics[J]. Chin J Appl Clin Pediatr(中华实用儿科临床杂志), 2018, 33(17): 1301-1308.
[11] LIU J, CUI Y, BAI M X, et al. Study on application of traditional Chinese medicine in prevention and treatment of novel coronavirus pneumonia[J]. Chin Tradit Herb Drugs(中草药), 2020,51(1):1-5.
[12] LI X J Y, LI Y J, GE J D, et al. Pharmacovigilance and protective medication for drug-induced liver injury in treatment of COVID-19[J]. Chin Tradit Herb Drugs(中草药), 2020, 51(4):851-859.
[13] CHEN Y W, TANG L Q, ZHANG S Y, et al. Rational administration and pharmaceutical care of interferon alpha nebulization therapy in coronavirus disease 2019[J/OL]. Chin Hosp Pharm J(中国医院药学杂志), 2020: 1～5. [2020-05-18]. http://kns.cnki.net/kcms/detail/42.1204.R.20200224.1905.007.html.
[14] YANG J, MO G D, LU Z J, et al. Characteristics analysis of 107 cases adverse drug reactions caused by interferon injection in our hospital[J]. Pharm Today(今日药学), 2017, 27(3): 199-201.
[15] ZHANG H, KANG Z J, GONG H Y, et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes [J]. BioRxiv, 2020. DOI:http://doi.org/10.1101/2020.0130.927806.
[16] WU Y, GUO C, TANG L, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples[J]. Lancet Gastroenterol Hepatol, 2020, 5(5): 434-435.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
上海市优秀学术/技术带头人计划项目资助(19XD1400900);上海市科学技术委员会科研计划项目资助(18DZ1910604);上海市卫生计生系统重要薄弱学科建设项目资助(2016ZB0305)
{{custom_fund}}
PDF(3160 KB)
